- Home
- MFIN vs CBIO Comparison
MFIN vs CBIO Comparison
Compare MFIN & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- CBIO
- Stock Information
- Founded
- MFIN 1995
- CBIO 2003
- Country
- MFIN United States
- CBIO United States
- Employees
- MFIN N/A
- CBIO N/A
- Industry
- MFIN Finance: Consumer Services
- CBIO
- Sector
- MFIN Finance
- CBIO
- Exchange
- MFIN Nasdaq
- CBIO Nasdaq
- Market Cap
- MFIN 243.9M
- CBIO 219.5M
- IPO Year
- MFIN 1996
- CBIO N/A
- Fundamental
- Price
- MFIN $10.03
- CBIO $15.22
- Analyst Decision
- MFIN Strong Buy
- CBIO Strong Buy
- Analyst Count
- MFIN 1
- CBIO 5
- Target Price
- MFIN $12.00
- CBIO $25.60
- AVG Volume (30 Days)
- MFIN 44.9K
- CBIO 64.3K
- Earning Date
- MFIN 10-29-2025
- CBIO 11-06-2025
- Dividend Yield
- MFIN 4.81%
- CBIO N/A
- EPS Growth
- MFIN 1.06
- CBIO N/A
- EPS
- MFIN 1.71
- CBIO N/A
- Revenue
- MFIN $338,783,000.00
- CBIO N/A
- Revenue This Year
- MFIN N/A
- CBIO N/A
- Revenue Next Year
- MFIN $3.82
- CBIO N/A
- P/E Ratio
- MFIN $5.83
- CBIO N/A
- Revenue Growth
- MFIN 15.53
- CBIO N/A
- 52 Week Low
- MFIN $7.71
- CBIO $9.81
- 52 Week High
- MFIN $10.98
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- MFIN 55.04
- CBIO 77.85
- Support Level
- MFIN $9.14
- CBIO $12.76
- Resistance Level
- MFIN $9.65
- CBIO $13.43
- Average True Range (ATR)
- MFIN 0.32
- CBIO 0.59
- MACD
- MFIN 0.02
- CBIO 0.17
- Stochastic Oscillator
- MFIN 87.24
- CBIO 91.71
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.